Pavli P, Triantafyllidou O, Kapantais E, Vlahos NF, Valsamakis G
Nausea and diarrhoea were the most common side effects which were transient and improved with time, with less than 5% TLDR summary: The SUSTAIN 6 trial looked at the cardiovascular outcomes (cardiovascular death, heart attack and stroke) in high cardiovascular risk diabetic patients being treated with semaglutide versus placebo- with the results showing a significant 26% reduction in cardiovascular death, heart attack and stroke in patients being treated with semaglutide The SUSTAIN 6 trial published in the New England Journal of Medicine showed that in patients with type 2 diabetes who were at high cardiovascular risk
Cost savings are not worth risking your health
When nausea typically improves A systematic review of semaglutide trials found nausea in 35 percent of patients during the first four weeks, dropping to 20 percent after 12 weeks
These drugs contain semaglutide, tirzepatide and other molecules that make people feel less hungry and often result in significant weight loss